Clinical Trial Update: A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial of ramelteon tablets for sublingual administration (TAK-375SL) in maintenance treatment of Bipolar I disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Ramelteon (ramelteon)

Snippet

Sponsor: Takeda | Conditions: Bipolar Disorder | Phase 3 | Status: WITHDRAWN